ASCO 2017: Circulating tumour cells and survival in abiraterone and enzalutamide treated patients with castration-resistant prostate cancer
Chicago, IL (UroToday.com) Dr. De Laere presented a study investigating the prognostic value of circulating tumor cells (CTC) enumeration and dynamics in the context of second-line endocrine therapies (i.e. abiraterone or enzalutamide) in patients with metastatic castrate-resistant prostate cancer (mCRPC).
ASCO 2017: Predictors of post-surgical race-specific prostate cancer progression
Chicago, IL (UroToday.com) Differences in prostate cancer (PCa) incidence and mortality for African American (AA) versus Caucasian American (CA) men may reflect tumor biology, comorbidity, treatment, follow-up care, and/or health care access. Dr. Jennifer Cullen presented a study including a racially diverse cohort of patients undergoing radical prostatectomy (RP). The study examined how race, comorbidity, and PSA doubling time (PSADT) impact PCa progression.
ASCO 2017: Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel in metastatic castration resistant prostate cancer
Chicago, IL (UroToday.com) Glutathione S-transferase (GSTP1) inactivation is associated with CpG island hypermethylation in > 90% prostate cancers. Detection of circulating mGSTP1 DNA predicts response to Docetaxel (DTX) and overall survival (OS) in phase I/II mCRPC cohorts. Dr. Mahon presented data from a post hoc analysis of a phase III study aiming to test the association between circulating mGSTP1 DNA levels and outcomes after 2 cycles of docetaxel (PRECYC3). The secondary objective was to see if baseline mGSTP1 predicts overall survival.
ASCO 2017: The aggressive variant prostate carcinoma molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer
Chicago, IL (UroToday.com) The aggressive variant prostate cancer (AVPC) are a subset of prostate cancers that share the clinical, therapy response, and molecular profiles of the small cell prostate carcinomas, a histological variant of the disease that responds poorly to androgen receptor directed therapies.
ASCO 2017: Identification of a CTC-based gene expression signature predicting resistance to abiraterone and enzalutamide in mCRPC
Chicago, IL (UroToday.com) Dr. Todd Morgan and collaborators presented their work at the ASCO 2017 prostate cancer poster session assessing a circulating tumor cell (CTC)-based gene expression signature predicting resistance to abiraterone and enzalutamide in mCRPC patients.
ASCO 2017: Baseline CTC subtype to predict outcomes on mCRPC patients receiving enzalutamide compared to abiraterone
Chicago, IL (UroToday.com) At the prostate cancer poster session at the 2017 ASCO annual meeting, Dr. Howard Scher and colleagues presented their data regarding baseline circulating tumor cell (CTC) subtypes as a way to predict outcomes of mCRPC patients receiving enzalutamide or abiraterone.
ASCO 2017: Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer
Chicago, IL (UroToday.com) Over the past several years, there has been increased interest in treatment of oligometastatic sites for patients with prostate cancer. At the prostate cancer poster session at the 2017 ASCO annual meeting, Dr. Phuoc Tran presented their findings of stereotactic ablative radiation therapy for treatment of oligometastatic prostate cancer. Stereotactic ablative radiotherapy (SABR) is highly focused, high-dose radiation that is well suited for treatment of oligometastases.